| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1008182929 |
| P356 | DOI | 10.1016/J.CLPT.2004.03.003 |
| P698 | PubMed publication ID | 15229462 |
| P5875 | ResearchGate publication ID | 8479956 |
| P50 | author | Chris Twelves | Q47067174 |
| Hans J. Gelderblom | Q59368817 | ||
| Alex Sparreboom | Q71780219 | ||
| Jaap Verweij | Q98683725 | ||
| P2093 | author name string | Howard L McLeod | |
| Sharon Marsh | |||
| Rosendo Obach | |||
| Paola Principe | |||
| Ranjeet Ahluwalia | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| diflomotecan | Q27287310 | ||
| P304 | page(s) | 38-44 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype | |
| P478 | volume | 76 |
| Q35617587 | A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? |
| Q51422445 | A novel simultaneous modeling approach to estimate linearity of pharmacokinetic parameters, including saturation of intestinal efflux, in the rat. |
| Q34586418 | ABC multidrug transporters: structure, function and role in chemoresistance. |
| Q35056738 | ABC transporters: unvalidated therapeutic targets in cancer and the CNS |
| Q45993642 | ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. |
| Q35016817 | ABCG2: a perspective. |
| Q36597410 | ATP-binding cassette, subfamily G (ABCG family). |
| Q39486373 | Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity |
| Q37020542 | Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. |
| Q37219909 | Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells |
| Q33704930 | Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe |
| Q37958162 | Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. |
| Q34444082 | Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics |
| Q47220295 | Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? |
| Q37069556 | Cancer therapies utilizing the camptothecins: a review of the in vivo literature |
| Q34702620 | Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR⁻) rats |
| Q80997948 | Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy |
| Q43258273 | Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin |
| Q38779504 | Discovery of 7-Methyl-10-Hydroxyhomocamptothecins with 1,2,3-Triazole Moiety as Potent Topoisomerase I Inhibitors |
| Q46967012 | Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes |
| Q36391044 | Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis |
| Q37793056 | Drug transport by breast cancer resistance protein. |
| Q37760954 | Drug transporter pharmacogenetics in nucleoside-based therapies. |
| Q53453616 | Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level |
| Q98302941 | Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy |
| Q33776950 | Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants |
| Q38071700 | Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications |
| Q90614437 | Ethnogeographic and inter-individual variability of human ABC transporters |
| Q28485221 | Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations |
| Q43080807 | Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67. |
| Q37790379 | Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy |
| Q57110508 | Gene-by-Environment Interaction of Bcrp-/- and MCD Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition |
| Q36733503 | Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter |
| Q37830057 | Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents |
| Q36410400 | Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer |
| Q37481450 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs |
| Q34663656 | Genetic variation: effect on prostate cancer. |
| Q38187646 | Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. |
| Q92150495 | Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2 |
| Q38888369 | Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant? |
| Q38003174 | Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. |
| Q62512297 | Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients |
| Q37811967 | In Vitro and In Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP/MXR/ABCP/ABCG2) |
| Q26795589 | Insights into Chemoresistance of Prostate Cancer |
| Q34415050 | Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis |
| Q28570070 | Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion |
| Q39923958 | Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations |
| Q36120816 | Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. |
| Q36659167 | Membrane transporter proteins: a challenge for CNS drug development. |
| Q37182212 | PhRMA white paper on ADME pharmacogenomics. |
| Q79563377 | Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer |
| Q46826559 | Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans |
| Q38933314 | Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review. |
| Q38242601 | Pharmacogenetics of membrane transporters: a review of current approaches. |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q37235629 | Pharmacogenomic importance of ABCG2. |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q36441493 | Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy |
| Q51355553 | Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. |
| Q38243832 | Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance |
| Q43737131 | Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors |
| Q39117848 | Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms |
| Q34774854 | Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance |
| Q36250753 | Role of the breast cancer resistance protein (ABCG2) in drug transport |
| Q34871636 | Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update |
| Q34579035 | SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers |
| Q50749129 | Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. |
| Q34176588 | Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) |
| Q37074550 | The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant. |
| Q36803379 | The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. |
| Q34968909 | The challenge of exploiting ABCG2 in the clinic. |
| Q37941758 | The controversial role of ABC transporters in clinical oncology. |
| Q42151027 | The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine |
| Q36935258 | The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro |
| Q37024001 | The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. |
| Q36052743 | The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). |
| Q38303543 | The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein |
| Q37537018 | The role of transporters in the pharmacokinetics of orally administered drugs |
| Q89797130 | Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species |
| Q82824298 | Two novel SNPs of the ABCG2 gene and its associations with milk traits in Chinese Holsteins |
| Q37958098 | Variation and evolution of the ABC transporter genes ABCB1, ABCC1, ABCG2, ABCG5 and ABCG8: implication for pharmacogenetics and disease |
| Q89834270 | Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells |
Search more.